AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Combining Stellate Ganglion Block With Prolonged Exposure for PTSD

RecruitingPhase 2Ages 18 Years - 65 YearsAllThe University of Texas Health Science Center at โ€ฆ
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The goal of this clinical trial is to compare the combination of Massed Prolonged Exposure (PE); a behavioral therapy for PTSD) and a stellate ganglion block (SGB; an injection of a local anesthetic into the front of the neck) with Massed Prolonged Exposure and a sham injection in a sample of military service members or retirees with PTSD. The main questions it aims to answer are: (1) Does the addition of an SGB improve treatment outcomes associated with Massed PE and (2) Do differences in psychophysiological arousal during the exposure portion of treatment help explain treatment outcomes for PTSD. Participants will receive ten 90-minute session of Massed PE. Between the first and second Massed PE sessions, half of the participants will receive a SGB, and half will receive a sham SGB.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Active duty and retired military service members ages 18-65 years 2. PTSD diagnosis as assessed by Clinician-Administered Posttraumatic Stress Scale 3. Able to speak and read English (due to standardization of outcome measures) 4. Defense Enrollment Eligibility Reporting System (DEERS)-eligible to receive care at a military treatment facility (MTF) where the stellate ganglion block will be placed. Exclusion Criteria: 1. Current suicidal ideation severe enough to warrant immediate attention (as determined by the Depressive Symptoms Index - Suicidality Subscale and the Self-Injurious Thoughts and Behaviors Interview short form) and corroborated by a clinical risk assessment by a credentialed provider. 2. Current manic episode or psychotic symptoms requiring immediate stabilization or hospitalization (as determined by clinical judgment) 3. Symptoms of moderate to severe substance use (to include alcohol) warranting immediate intervention based on clinical judgment. 4. Other psychiatric disorders severe enough to warrant designation as the primary disorder as determined by clinician judgment 5. Pregnancy or breastfeeding 6. Current anticoagulant use 7. History of bleeding disorder 8. Infection or mass at injection site 9. Myocardial infarction within 6 months of procedure 10. Pathologic bradycardia or irregularities of heart rate or rhythm 11. Symptomatic hypotension 12. Phrenic or laryngeal nerve palsy 13. History of glaucoma 14. Uncontrolled seizure disorder 15. History of allergy to local anesthetics 16. Current use of Class III antiarrhythmics
๐Ÿ’Š

What it tests

  • Ropivacaine injection
  • Normal saline
๐Ÿ“

Where

2 sites
Carl R. Darnall Army Medical Center
Fort Hood, United States
University of Texas Health Science Center at San Antonio
San Antonio, United States
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy